Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Insulin

Preparation Calculator

USE IF: Diabetes mellitus, DKA, hyperglycemia, hyperkalemia (with glucose)

AVOID IF: Untreated hypoglycemia, inability to monitor glucose safely

Insulin (General / Core)

Antihyperglycemic hormone therapy (type-specific kinetics)

AdultPediatricEndocrineERICUHigh-yield

Indication

Diabetes • DKA • Hyperglycemia • Hyperkalemia (adjunct)

At a glance

INDICATIONS (CORE USE)

- Diabetes management - DKA (IV infusion) - Hyperkalemia (with glucose)

ADULT DOSE (STANDARD)

Highly protocol-based and insulin-type specific IV infusion in acute pathways; SC for maintenance regimens

MAX DOSE

No single universal maximum; titrate by protocol, glucose trend, and safety monitoring

Route

IV • SC

PEDIATRIC DOSE

Protocol-based

Do not miss

Must-not-miss safety points

Major warning

- Hypoglycemia can be life-threatening - Requires frequent glucose monitoring - Intracellular potassium shift can cause hypokalemia - In hyperkalemia, pair insulin with glucose unless already markedly hyperglycemic

Institutional protocol required

Dosing for this medication is not a substitute for your hospital order set, pharmacy verification, or specialty protocol. Use only with an approved institutional pathway, continuous monitoring, and independent double-check where policy requires.

FMBM beta: decision support only — not medical advice or a prescribing system.

Indications

INDICATION: Diabetes • DKA • Hyperglycemia • Hyperkalemia (adjunct)

Primary

  • Diabetes mellitus

Secondary

  • DKA
  • Hyperkalemia (adjunct)

Institutional protocol required

Dosing for this medication is not a substitute for your hospital order set, pharmacy verification, or specialty protocol. Use only with an approved institutional pathway, continuous monitoring, and independent double-check where policy requires.

Numeric examples in this monograph are illustrative only when present — always follow your verified institutional protocol and product labeling.

FMBM beta: decision support only — not medical advice or a prescribing system.

Dosing

STANDARD (ADULT PO)

Protocol-driven; regimen depends on insulin type, indication, and care setting

ADULT DOSE

GENERAL: - Highly protocol-based - Varies by insulin type and indication DKA: - IV infusion protocol - Adjust using glucose trend and anion gap HYPERKALEMIA: - IV insulin with glucose

PEDIATRIC DOSE

Protocol-based

MAX DOSE

No fixed universal maximum; safety is defined by glucose/potassium response and protocol endpoints

Practical Note

- Distinguish insulin type and route before prescribing or administering - Use standardized order sets to avoid unit-vs-mL errors - Acute regimens require frequent reassessment

Warnings

Clinical warnings

  • Use only with an approved institutional order set and pharmacy verification — this monograph is clinical decision support, not standalone prescribing authority.
  • Hypoglycemia
  • Hypokalemia
  • Dosing errors (units vs mL)

Adverse effects

  • Hypoglycemia
  • Weight gain (chronic use)

Contraindications

  • Hypoglycemia

Drug interactions

  • Other hypoglycemics increase risk of clinically significant hypoglycemia

Special populations

Pediatrics

Protocol-based

Pregnancy

Pregnancy: Use protocol-guided insulin strategies with close glucose targets

Lactation

Use with routine glucose monitoring and regimen adjustment as needed.

Renal impairment

Increased insulin sensitivity and reduced clearance can raise hypoglycemia risk; dose conservatively and monitor closely.

Hepatic impairment

Hepatic dysfunction can alter glucose handling and insulin requirements; frequent reassessment is needed.

Elderly

Higher hypoglycemia risk and consequences; simplify regimens where possible and monitor closely.

Administration

- IV for acute use - SC for maintenance - Must follow protocol

Monitoring

  • Monitor: - Glucose (frequent) - Potassium (acute use) - Clinical response
  • Recheck: - Hourly in DKA pathways - After hyperkalemia treatment
  • Hold / reassess: - Hypoglycemia - Rapid glucose drop

Overdose / toxicity

Clinical Picture

Hypoglycemia and neuroglycopenia

Immediate Actions

Immediate glucose administration and supportive care

Antidote

Glucose

Decontamination

Supportive management with repeated glucose reassessment

Escalation

Escalate for persistent/recurrent hypoglycemia or neurologic compromise

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Most dangerous error is hypoglycemia

Clinical

  • In normoglycemic hyperkalemia, pair insulin with glucose

Safety

  • Units errors are common and dangerous; use protocolized order sets

Pharmacy Tool

Insulin Safety Tool

FMBM beta: no compounding calculator for insulin. Use institutional order sets and pharmacy verification for all doses.

  • Insulin is a high-alert medication.
  • Insulin is dosed in UNITS, not mg or mL - never convert without confirming concentration.
  • Do not compound or scale insulin using the standard preparation calculator.
  • Verify insulin type, concentration, device, route, dose units, and timing before administration.
  • Confirm U-100 vs concentrated insulin formulations such as U-200, U-300, and U-500.
  • IV insulin requires dedicated protocols and continuous monitoring; do not interchange with subcutaneous dosing.
  • Coordinate insulin dosing with meals; mismatches increase hypoglycemia risk.
  • Hypoglycemia risk - ensure access to rapid glucose and follow institutional hypoglycemia protocol.
  • Use institutional insulin protocols for correction dosing, basal-bolus regimens, IV insulin infusions, and DKA management.
  • Double-check dose with another clinician/pharmacist when required by policy.

Pharmacokinetics

- Kinetics vary by insulin type and route

Mechanism of action

- Promotes glucose uptake and intracellular potassium shift

Common brand names

Saudi Arabia

Lantus, Humalog, Novorapid, Tresiba

Global

Novolog, Insulin, Regular insulin, Basal insulin (class examples), (placeholder — verify local formulation)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Product labeling (insulin products)
  • Local DKA and hyperkalemia protocols
  • Institutional insulin safety guidance